Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05277376 · ClinicalTrials.gov registry record · Phase 3
Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial
A Phase 3 study, sponsored by dsm-firmenich Switzerland.
- Completed
- Registry status
- Phase 3
- Development phase
- 162
- Enrollment target
NCT05277376: Completed Phase 3 study, sponsored by dsm-firmenich Switzerland.
NCT05277376 is a Phase 3 study that has completed, run by dsm-firmenich Switzerland. The registered enrollment target is 162 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05277376, a Phase 3 study, has completed, sponsored by dsm-firmenich Switzerland.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 162 participants
- Enrollment target
Study Summary
An open-label, randomized, 3-arm study in 162 healthy adult subjects with the following primary objective: To assess the systemic absorption and pharmacokinetics of BEMT from 3 market image sunscreen formulations under maximal-use conditions.
Primary Outcome
Assess Cmax (maximum observed drug concentration) of BEMT in plasma from three high-penetrating sunscreen formulations under maximal-use conditions computed for Overall, Day 1, and Day 4. With the time intervals for Overall and Days 1, 2, 3, and 4 defined as: Overall = 0 to 264 hours; Day 1 = 0 to 23.5 hours; Day 2 = 23.5 to 47.5 hours; Day 3 = 47.5 to 71.5 hours; and Day 4 = 71.5 to 96 hours.
Interventions
- DRUG Bemotrizinol (6%)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2022-10-28 |
| Phase | Phase 3 |
What the finished NCT05277376 record still lists
NCT05277376 is an interventional study that assigns participants to a tested intervention. The registered 162 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (79% lower).
The record links to 0 conditions, and to 1 intervention - of which Bemotrizinol (6%) is the first listed.
NCT05277376 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05277376 about?
NCT05277376 is a clinical study titled "Pharmacokinetic (PK) Evaluation of Bemotrizinol (6%) in a Sunscreen Maximum Usage Trial". An open-label, randomized, 3-arm study in 162 healthy adult subjects with the following primary objective: To assess the systemic absorption and pharmacokinetics of BEMT from 3 market image sunscreen formulations under maximal-use conditions.
What is the current status of trial NCT05277376?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 162 participants. The study started on 2022-03-15. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT05277376?
The interventions under investigation include: Bemotrizinol (6%) (DRUG).
Who is sponsoring clinical trial NCT05277376?
This trial is sponsored by dsm-firmenich Switzerland, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05277376's enrollment target sits among peer trials
162 1474th of 2000 higher than 523 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02347111 · 162 participants · Phase 4
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
- NCT02610426 · 162 participants
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
- NCT05040711 · 162 participants · NA
mHealth Mindfulness With Patients With Serious Illness and Their Caregivers
- NCT05514717 · 162 participants · Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI